becton dickinson compani
summari report result in-lin
consensu forecast provid ep guidanc
street expect ep beat consensu
estim ep miss vs model primarili
reflect slightli lower revenu gross margin partli off-set
lower tax rate total revenu grew
consensu miss estim
manag guid compar sale growth
consist preliminari expect low-end
rang ex-btk below-the-kne set call ep
guidanc report growth
previou expect report double-digit growth worsen
fx headwind like account increment pressur
new ceo tom polen set step start jan believ
like built addit conservat outlook
especi emerg increment headwind
roll forward valuat basi lower
price target base blend price-to-earnings
ep ev/ebitda
ebitda
sale growth closer low-end expect
expect growth toward low-end exclud
btk manag offici narrow rang guid
sale growth bd medic guidanc growth
growth lower would expect
basic medic suppli medic deliveri system md
certain part china diabet well impact order
time relat pend alari pump softwar upgrad
us medic manag system bd lifesci
ls expect sale growth consist
perform ahead growth
manag sound confid high-singl digit growth
diagnost system bioscienc year bd
intervent bdi guidanc growth seem somewhat
conserv rel growth consist
growth believ solid growth momentum
continu uptak recent new launch forecast
total revenu
compar growth fx headwind
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
includ bcr acquisit start ep calcul use two method
determin impact prefer convert as-convert
assum mandatori convert prefer mandatorili convert
compani data secur llc estim reuter
continu previou page
ep guidanc expect due increment headwind call
subsequ investor confer manag sound confid deliv double-digit report
ep growth howev actual guidanc report growth
includ headwind fx due expir gore royalti relat
china tariff compar call worsen headwind includ fx gore
sens may smaller addit headwind increment cost
relat remedi ga steril plan may put modest addit pressur
bottom-lin growth underli basi exclud headwind project ep growth
like conservat built ep guidanc fx estim
cushion given currenc volatil compani experi worsen fx impact
said believ would challeng expect meaning increment leverag
drive ep growth buy back share time like reach leverag
toward end year lower ep estim yr/yr growth
outlook reflect major headwind may prove conserv guid
compar sale growth due sever headwind includ time alari pump
softwar upgrad us push sale price pressur part china basic
medic suppli cathet new tender process tough comp system
due time order benefit last year flattish perform diabet due price pressur
continu tough yr/yr comp dcb fx headwind top-lin growth
expect well sale growth growth net-net compani
expect ep declin midpoint rang includ fx
headwind ep ex-fx tom polen expect host first earn call ceo believ
compani like built suffici conservat outlook leav room potenti upsid
vs sale growth cadenc expect similar expect compar
sale growth full year guidanc base guidanc
growth impli growth acceler faster growth also reflect easier
yr/yr comp easiest quarter comp impli sale growth better
vs sale growth cadenc appear similar improv ep growth beyond
driven faster sale growth gross margin improv fx headwind eas declin interest
expens continu pay debt reduc gore royalti headwind
perform somewhat mix sale growth acceler two three key segment
ep ex-fx beat consensu estim ep miss vs
model primarili reflect slightli lower revenu gross margin vs estim
partli off-set lower tax rate vs estim total revenu
compar ex-fx pro forma bcr ex-divestitur exceed consensu miss
estim segment sale growth improv bd ls bdi bd medic
compar sale growth slow due deceler md bd ls
compar sale acceler driven faster growth diagnost system
bioscienc bdi sale grew underli driven acceler three
key busi peripher intervent sale growth acceler despit
improv dcb perform non-dcb sale grew low-doubl digit
materi chang dcb market outlook sinc updat fda letter aug compani note
signific chang demand continu expect declin rel plan impact
anniversari believ continu maintain share shrink market btk
compani plan submit addit data like long-term safeti data trial registri data
fda next coupl month manag commentari decis offici narrow
top-lin guidanc exclud btk seem suggest perhap less confid btk approv although
sens optim remain btk approv would repres upsid guidanc
analyst day set may nyc hope gain better visibl key driver
bdx acceler growth stori analyst day time also expect hear
bdx capit deploy strategi financi profil outlook post initi bcr
integr period track achiev gross leverag end expect
acceler mostli tuck-in acquisit resum share repurchas thereaft
becton dickinson compani
metricswfconsensuswfconsensusrevenu medic manag deliveri critic factset wfconsensusrevenu profit incom compani report secur llc estim factset visibl alpha explicitli state consensu visibl alpha may vari base broker contribut vs actual vs medic technolog
price target
price target base blend ev/ebitda ebitda price-to-earnings
estim risk includ slower expect integr bcr lower expect cost
save accret bcr unexpect delay debt pay unexpect pipelin delay/setback
believ solidli posit deliv mid-singl digit top-lin growth low double-digit
bottom-lin growth forese futur
global medic devic compani oper two key segment medic life
scienc pend bcr acquisit add third leg platform intervent grew
revenu nearli pro forma underli basi
becton dickinson compani
